Literature DB >> 18574277

Acute ST-segment elevation myocardial infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Shaun G Goodman1, Venu Menon2, Christopher P Cannon3, Gabriel Steg4, E Magnus Ohman5, Robert A Harrington5.   

Abstract

This chapter about fibrinolytic, antiplatelet, and antithrombin treatment for acute ST-segment elevation (STE) myocardial infarction (MI) is part of the American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Grade 1 recommendations are strong and indicate that the benefits do, or do not, outweigh risks, burden, and costs. Grade 2 suggests that individual patient values may lead to different choices (for a full understanding of the grading see the chapter by Guyatt et al, CHEST 2008; 133[suppl]:123S-131S). Among the key recommendations in this chapter are the following: for patients with ischemic symptoms characteristic of acute MI of < or = 12 h in duration and persistent STE, we recommend that all undergo rapid evaluation for reperfusion (primary percutaneous coronary intervention [PCI] or fibrinolytic) therapy and have a reperfusion strategy implemented promptly after contact with the health-care system (Grade 1A). For patients with ischemic symptoms characteristic of acute MI of < or = 12 h in duration and persistent STE, we recommend administration of streptokinase, anistreplase, alteplase, reteplase, or tenecteplase over no fibrinolytic therapy (all Grade 1A). For patients with symptom duration < or = 6 h, we recommend the administration of alteplase or tenecteplase over streptokinase (both Grade 1A). We recommend aspirin over no aspirin therapy followed by indefinite therapy (Grade 1A); we also recommend clopidogrel in addition to aspirin for up to 28 days (Grade 1A). In addition to aspirin and other antiplatelet therapies, we recommend the use of antithrombin therapy (eg, unfractionated heparin (UFH), enoxaparin, or fondaparinux) over no antithrombin therapy (Grade 1A), including for those patients receiving fibrinolysis (and regardless of which lytic agent is administered), primary PCI, or patients not receiving reperfusion therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18574277     DOI: 10.1378/chest.08-0665

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  19 in total

Review 1.  Manifold beneficial effects of acetyl salicylic acid and nonsteroidal anti-inflammatory drugs on sepsis.

Authors:  Damon P Eisen
Journal:  Intensive Care Med       Date:  2012-04-25       Impact factor: 17.440

Review 2.  Pre PCI hospital antithrombotic therapy for ST elevation myocardial infarction: striving for consensus.

Authors:  S Michael Gharacholou; Brenda J Larson; Christian C Zuver; Ryan J Wubben; Giorgio Gimelli; Amish N Raval
Journal:  J Thromb Thrombolysis       Date:  2012-07       Impact factor: 2.300

Review 3.  Role of thrombolysis in reperfusion therapy for management of AMI: Indian scenario.

Authors:  Jamshed Dalal; Prasant Kumar Sahoo; Rakesh Kumar Singh; Anil Dhall; Rajneesh Kapoor; A Krishnamurthy; Sadanand R Shetty; Shailendra Trivedi; Dhiman Kahali; Bhupesh Shah; K Chockalingam; Jabir Abdullakutty; Pradeep K Shetty; Arun Chopra; Raja Ray; Devang Desai; Gajanan Ratnaparkhi; Mridul Sharma; K A Sambasivam
Journal:  Indian Heart J       Date:  2013-09-23

Review 4.  Antithrombotic therapy in acute coronary syndromes: guidelines translated for the clinician.

Authors:  S Michael Gharacholou; Renato D Lopes; Jeffrey B Washam; L Kristin Newby; Stefan K James; John H Alexander
Journal:  J Thromb Thrombolysis       Date:  2010-05       Impact factor: 2.300

Review 5.  Optimizing the use of thrombolytics in ST-segment elevation myocardial infarction.

Authors:  Michael A Morse; Josh W Todd; George A Stouffer
Journal:  Drugs       Date:  2009-10-01       Impact factor: 9.546

6.  Systemic thrombolysis in acute pulmonary embolism: also a matter of "time".

Authors:  Marco Zuin; Loris Roncon
Journal:  J Thromb Thrombolysis       Date:  2017-02       Impact factor: 2.300

7.  Clopidogrel versus Other Antiplatelet Agents for Secondary Prevention of Vascular Events in Adults with Acute Coronary Syndrome or Peripheral Vascular Disease: Clinical and Cost-Effectiveness Analyses.

Authors:  S Banerjee; A Brown; L McGahan; K Asakawa; B Hutton; M Clark; M Severn; M Sharma; Jl Cox
Journal:  CADTH Technol Overv       Date:  2012-03-01

Review 8.  Usual and unusual care: existing practice control groups in randomized controlled trials of behavioral interventions.

Authors:  Kenneth E Freedland; David C Mohr; Karina W Davidson; Joseph E Schwartz
Journal:  Psychosom Med       Date:  2011-05-02       Impact factor: 4.312

Review 9.  Low molecular weight heparin for the treatment of retinal vein occlusion: a systematic review and meta-analysis of randomized trials.

Authors:  Alejandro Lazo-Langner; Jeff Hawel; Walter Ageno; Michael J Kovacs
Journal:  Haematologica       Date:  2010-03-19       Impact factor: 9.941

10.  Fondaparinux and acute coronary syndromes: update on the OASIS 5-6 studies.

Authors:  François Schiele
Journal:  Vasc Health Risk Manag       Date:  2010-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.